Biotech M&A – 2024 Deals

Biotech M&A – 2024 Deals

Biotech M&A With a Quick Start in 2024!

Is There Any Chance to Beat 2023 Numbers ?

DateAcquirer Co.Acquirer TickerAcquired Co.Acquired TickerDeal valuePrice/ShareNotesLink to the news PR
01/08/2024MerckMRKHarpoon TherapeuticsHARP$680M$23.00 delta-like ligand 3 (DLL3) targeting T-cellhttps://t.co/lKw5RpfMDa
01/08/2024Johnson & JohnsonJNJAmbrx BiopharmaAMAM$2B$28.00PSMA-Targeting Antibody Drug Conjugate (ADC)https://t.co/KVdMV156lq
01/08/2024Boston ScientificBSXAxonicsAXNX$3.7B$71.00 urology- to treat urinary and bowel dysfunctionhttps://t.co/M5mkLVP0Gs
01/08/2024NovartisNVSCalypso Biotech BVPrivate$250M-anti-IL-15 monoclonal antibody, ermatology, gastro-intestinalhttps://t.co/RuEPTZgwtT
01/09/2024GSKGSKAiolos BioPrivate$1B-$400M milestone
respiratory pipeline
https://t.co/TgVfySS20h
01/23/2024SanofiSNYInhibrx, Inc.INBX$1.7B$30 + $5 CVR + 0.25 shares of a “New Inhibrx”Rare disease asset for Alpha-1 Antitrypsin Deficiency-AATDhttps://t.co/Uu11tmTru2
2/12/2024Gilead GLD CymaBay Therapeutics CBAY$4.3B$32.50PPARδ Agonist for the Treatment of Primary Biliary Cholangitis (PBC) with FDA Priority Review & Q3 Anticipated Approvalhttps://t.co/ailcDNL2eC

For M&A 2023 full table click here https://www.chimeraresearchgroup.com/biotech-ma-2023/

Recent Press

Slider

Log In

JoinLost Password?